Single-Cell RNA Sequencing Reveals Cellular Heterogeneity in an Acral Amelanotic Melanoma After Immunotherapy Treatment

References

• Granier C, De Guillebon E, Blanc C, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017;2(2):e000213. doi:10.1136/esmoopen-2017-000213
   PubMed Web of Science ®Google Scholar
• Economopoulou P, Kotsantis I, Bamias A. A drug safety evaluation of atezolizumab in locally advanced or metastatic urothelial carcinoma. Expert Opin Drug Saf. 2020;19(8):955–960. doi:10.1080/14740338.2020.1792442
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–562. doi:10.1038/nature13904
   PubMed Web of Science ®Google Scholar
• Hamid O, Molinero L, Bolen CR, et al. Safety, clinical activity, and biological correlates of response in patients with metastatic melanoma: results from a Phase I trial of atezolizumab. Clin Cancer Res. 2019;25(20):6061–6072. doi:10.1158/1078-0432.CCR-18-3488
   PubMed Web of Science ®Google Scholar
• Huis In’t Veld EA, van Seventer IC, van Teeseling L, van Thienen JV, Crijns MB. Is routine skin examination in metastatic melanoma patients treated with immuno- or targeted therapy necessary? J Eur Acad Dermatol Venereol. 2020;34(4):e175–e176. doi:10.1111/jdv.16128
   PubMed Web of Science ®Google Scholar
• Nanda JK, Dusza SW, Navarrete-Dechent C, Liopyris K, Marghoob AA, Marchetti MA. Incidence of new primary cutaneous melanoma in patients with metastatic melanoma treated with immune checkpoint inhibitors: a single-center cohort study. JAMA Dermatology. 2021;157(1):79–83. doi:10.1001/jamadermatol.2020.3671
   PubMed Web of Science ®Google Scholar
• Thomas NE, Kricker A, Waxweiler WT, et al. Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study. JAMA Dermatol. 2014;150(12):1306–1314. doi:10.1001/jamadermatol.2014.1348
   PubMed Web of Science ®Google Scholar
• Phan A, Touzet S, Dalle S, Ronger-Salvé S, Balme B, Thomas L. Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br J Dermatol. 2006;155(3):561–569. doi:10.1111/j.1365-2133.2006.07368.x
   PubMed Web of Science ®Google Scholar
• Pizzichetta MA, Talamini R, Stanganelli I, et al. Amelanotic/hypomelanotic melanoma: clinical and dermoscopic features. Br J Dermatol. 2004;150(6):1117–1124. doi:10.1111/j.1365-2133.2004.05928.x
   PubMed Web of Science ®Google Scholar
• Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573–3587.e29. doi:10.1016/j.cell.2021.04.048
   PubMed Web of Science ®Google Scholar
• Hafemeister C, Satija R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 2019;20(1):296. doi:10.1186/s13059-019-1874-1
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Trapnell C, Cacchiarelli D, Grimsby J, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotechnol. 2014;32(4):381–386. doi:10.1038/nbt.2859
   PubMed Web of Science ®Google Scholar
• Cohen DN, Lumbang WA, Boyd AS, Sosman JA, Zwerner JP. Spindle cell squamous carcinoma during BRAF inhibitor therapy for advanced melanoma: an aggressive secondary neoplasm of undetermined biologic potential. JAMA Dermatol. 2014;150(5):575–577. doi:10.1001/jamadermatol.2013.7784
   PubMed Web of Science ®Google Scholar
• Wu JH, Cohen DN, Rady PL, Tyring SK. BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management. Br J Dermatol. 2017;177(4):914–923. doi:10.1111/bjd.15348
   PubMed Web of Science ®Google Scholar
• Anand K, Ensor J, Pingali SR, et al. T-cell lymphoma secondary to checkpoint inhibitor therapy. J Immunother Cancer. 2020;8(1):e000104. doi:10.1136/jitc-2019-000104
   PubMed Web of Science ®Google Scholar
• Gong HZ, Zheng HY, Li J. Amelanotic melanoma. Melanoma Res. 2019;29(3):221–230. doi:10.1097/CMR.0000000000000571
   PubMed Web of Science ®Google Scholar
• Kaizer-Salk KA, Herten RJ, Ragsdale BD, Sengelmann RD. Amelanotic melanoma: a unique case study and review of the literature. BMJ Case Rep. 2018;bcr-2017–222751. doi:10.1136/bcr-2017-222751
   Google Scholar
• Gupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C. Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell. 2019;24(1):65–78. doi:10.1016/j.stem.2018.11.011
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44. doi:10.1016/j.cell.2016.02.065
   PubMed Web of Science ®Google Scholar
• Escobar-Hoyos L, Knorr K, Abdel-Wahab O. Aberrant RNA splicing in cancer. Annu Rev Cancer Biol. 2019;3(1):167–185. doi:10.1146/annurev-cancerbio-030617-050407
   PubMedGoogle Scholar
• Kholmanskikh O, van Baren N, Brasseur F, et al. Interleukins 1α and 1β secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens. Int J Cancer. 2010;127(7):1625–1636. doi:10.1002/ijc.25182
   PubMed Web of Science ®Google Scholar
• Przybyla A, Zhang T, Li R, Roen DR, Mackiewicz A, Lehmann PV. Natural T cell autoreactivity to melanoma antigens: clonally expanded melanoma-antigen specific CD8 + memory T cells can be detected in healthy humans. Cancer Immunol Immunother. 2019;68(5):709–720. doi:10.1007/s00262-018-02292-7
   PubMed Web of Science ®Google Scholar
• Ding L, Odunsi K, Phimister EG. RNA splicing and immune-checkpoint inhibition. N Engl J Med. 2021;385(19):1807–1809. doi:10.1056/NEJMcibr2110736
   PubMed Web of Science ®Google Scholar
• Lu SX, De Neef E, Thomas JD, et al. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 2021;184(15):4032–4047.e31. doi:10.1016/j.cell.2021.05.038
   PubMed Web of Science ®Google Scholar
• Hoek KS, Eichhoff OM, Schlegel NC, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008;68(3):650–656. doi:10.1158/0008-5472.CAN-07-2491
   PubMed Web of Science ®Google Scholar
• Arozarena I, Wellbrock C. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. 2019;19(7):377–391. doi:10.1038/s41568-019-0154-4
   PubMed Web of Science ®Google Scholar
• Bonfanti P, Barrandon Y, Cossu G. “Hearts and bones”: the ups and downs of ‘plasticity’ in stem cell biology. EMBO Mol Med. 2012;4(5):353–361. doi:10.1002/emmm.201200220
   PubMed Web of Science ®Google Scholar
• Tu X, Qin B, Zhang Y, et al. PD-L1 (B7-H1) Competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy. Mol Cell. 2019;74(6):1215–1226.e4. doi:10.1016/j.molcel.2019.04.005
   PubMed Web of Science ®Google Scholar
• Li CW, Lim SO, Chung EM, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33(2):187–201.e10. doi:10.1016/j.ccell.2018.01.009
   PubMed Web of Science ®Google Scholar
• Massi D, Pinzani P, Simi L, et al. BRAF and KIT somatic mutations are present in amelanotic melanoma. Melanoma Res. 2013;23(5):414–419. doi:10.1097/CMR.0b013e32836477d4
   PubMed Web of Science ®Google Scholar
• Zhang M, Yang H, Wan L, et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol. 2020;73(5):1118–1130. doi:10.1016/j.jhep.2020.05.039
   PubMed Web of Science ®Google Scholar